Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New York ephedra bill

This article was originally published in The Tan Sheet

Executive Summary

Legislation to "ban the sale of supplements that contain ephedra in New York State except for the drugs under FDA supervision" recently introduced in state assembly. FDA's recent warning label proposal "fails to adequately address the risks" of ephedra, assemblywoman Audrey Pheffer says in March 19 comments to FDA urging national ban of the botanical. Bill A 6921, introduced March 12, would institute fines "of not more than $500 per violation" and statewide ban would apply to synthetic and natural forms sold as "Sea Grape, Yellow Horse, Country Mallow...Teamster's Tea and Yellow Astringent," among others, legislation states...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel